A Dose Block-randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation, Phase I Clinical Study

Trial Profile

A Dose Block-randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation, Phase I Clinical Study

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs KL 1333 (Primary)
  • Indications MELAS syndrome; Mitochondrial disorders
  • Focus Adverse reactions; First in man
  • Sponsors KT&G Life Sciences; Yungjin Pharm Co
  • Most Recent Events

    • 27 Jun 2017 Planned number of patients changed from 10 to 60, according to a NeuroVive Pharmaceutical media release.
    • 27 Jun 2017 According to a NeuroVive Pharmaceutical media release, first healthy volunteer has been enrolled in the study. The principal investigator for the study is Professor Kyung-Sang Yu MD, PhD at the Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine.
    • 27 Jun 2017 Status changed from not yet recruiting to recruiting, according to a NeuroVive Pharmaceutical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top